Antiverse

Antiverse is a Cardiff-based company using machine learning to identify diverse and rare antibody candidates from next-generation sequencing data of naïve and immune repertoires.

Its AI-augmented discovery platform analyses NGS data in silico to shortlist effective and developable antibodies, claiming a tenfold improvement in hit rates compared to conventional approaches.

The platform is already in use with large pharmaceutical companies and is being expanded to a broader customer base targeting oncology, cardiovascular, and respiratory indications.